Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis

Clinical Rheumatology

Volumn 34, Issue 9, 2015, Pages 1529-1536

  Restrepo, José Félix ^a   del Rincón, Inmaculada ^a   Battafarano, Daniel F ^b   Haas, Roy W ^a   Doria, Merced ^a   Escalante, Agustín ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

Anti cyclic citrullinated antibodies; Erythrocyte sedimentation; HLA DRB1; Interstitial lung disease; Rheumatoid arthritis; Rheumatoid factor; Smoking

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DRB1 ANTIGEN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DAS28; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; INTERSTITIAL LUNG DISEASE; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; SUBCUTANEOUS NODULE; AGED; ALLELE; ARTHRITIS, RHEUMATOID; COMPLICATION; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; RISK FACTOR; STATISTICAL MODEL; TEXAS;

ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DRB1 CHAINS; HUMANS; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; RISK FACTORS; SMOKING; TEXAS;

EID: 84940437361     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3025-8     Document Type: Article

References (43)

1. Brown KK (2007) Rheumatoid lung disease. Proc Am Thorac Soc 4:443–448
2. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168:159–166
3. Turesson C, Jacobsson LT (2004) Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33:65–72
4. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, Siegelman S, Connors G, Robinson WH, Bathon JM (2014) Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 73:1487–1494
5. Vittecoq O, Lequerre T, Goeb V, Le Loet X, Abdesselam TA, Klemmer N (2008) Smoking and inflammatory diseases. Best Pract Res Clin Rheumatol 22:923–935
6. Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH (2009) Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 68:201–208
7. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L (2006) Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2:425–433
8. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, Alfredsson L (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70:508–511
9. Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, Waldron JA (2000) Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 152:307–315
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
11. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
12. van der Heijde DM, van ’t Hof M, van Riel PL, van de Putte LB (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20:579–581
13. del Rincon I, Escalante A (1999) HLA-DRB1 alleles associated with susceptibility or resistance to rheumatoid arthritis, articular deformities, and disability in Mexican Americans. Arthritis Rheum 42:1329–1338
14. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Charron D, Dupont B, Erlich HA, Fauchet R, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI (1997) Nomenclature for factors of the HLA system, 1996. Tissue Antigens 49:297–321
15. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583–1591
16. Restrepo JF, Del Rincon I, Haas R, Battafarano DF, Escalante A (2013) A novel index to identify interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 65:S560
17. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62:722–727
18. Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL (2011) Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 38:983–989
19. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Murphy J, Cohen M, Raghu G, Brown KK (2011) Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372–378
20. Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R (2003) Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 62:897–900
21. Mori S, Cho I, Koga Y, Sugimoto M (2008) Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 35:1513–1521
22. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M (2005) Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 25:429–435
23. Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J (1994) Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 21:33–36
24. Hill Sir AB (1977) A short textbook of medical statistics. Hodder and Stoughton, London
25. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–37
26. van der Helm-van Mil AH, Huizinga TW (2008) Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 10:205
27. Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J (2005) Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52:3424–3432
28. Balsa A, Cabezon A, Orozco G, Cobo T, Miranda-Carus E, Lopez-Nevot MA, Vicario JL, Martin-Mola E, Martin J, Pascual-Salcedo D (2010) Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther 12:R62
29. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, Breedveld FC, Toes RE, Huizinga TW (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371
30. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC (2010) Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum 62:369–377
31. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L (2004) A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50:3085–3092
32. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, Hajeer AH, Ollier WE (2002) Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum 47:403–407
33. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L (2009) Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 60:1597–1603
34. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46
35. Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, Schwartz DA (1996) Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39:1711–1719
36. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M (2004) Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 14:272–280
37. Hamad MB, Marzouk S, Kaddour N, Masmoudi H, Fakhfakh F, Rebai A, Bahloul Z, Maalej A (2014) Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity. J Clin Lab Anal 28:21–26
38. Onder B, Kurtaran A, Kimyon S, Selcuk B, Akyuz M (2009) Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 30:223–227
39. Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, Giannakou A, Galanopoulou VK (2008) Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Clin Rev Allergy Immunol 34:11–15
40. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, Ryu JH, Baeten D, Matteson EL (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 46:70–75
41. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K (2008) Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 41:1074–1077
42. Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, Huie TJ, Stevens AD, Gill MB, Rabinovitch AM, Lynch DA, Burns DA, Pineiro IS, Groshong SD, Duarte Achcar RD, Brown KK, Martin RJ, Swigris JJ (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 106:1040–1047
43. Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, Weisman MH, Norris JM, Holers VM, Deane KD (2013) Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 65:2545–2554